Gabapentin NDC 81033-124

NDC codes

FDA NDC Directory

Product NDC (as listed)81033-124Labeler and product segments. Claims need a package NDC.

Product NDC at billing width81033-0124Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
81033-124-44	81033012444	40 CUP, UNIT-DOSE in 1 CARTON (81033-124-44) / 6 mL in 1 CUP, UNIT-DOSE (81033-124-06)Marketed from Sep 1, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Gabapentin
Generic name (nonproprietary): gabapentin
Active ingredients: Gabapentin — 50 mg/mL
Dosage form: Solution
Route: Oral
Labeler: Kesin Pharma Corporation
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 091286
Marketing start: Aug 6, 2025
Listing expires: Dec 31, 2026
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 81033-124_3f2ba3d6-6087-eaf2-e063-6294a90a7642SPL ID 3f2ba3d6-6087-eaf2-e063-6294a90a7642SPL set ID 3f2ba3d6-6086-eaf2-e063-6294a90a7642RxCUI 283523UNII 6CW7F3G59X

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N481033012444 followed by a unit qualifier and the quantity

Package 81033-0124-44. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 19, 2025.

Indications (excerpt from the label)

Gabapentin oral solution is indicated for: Management of postherpetic neuralgia in adults Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy Gabapentin oral solution is indicated for: Postherpetic neuralgia in adults (1) Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy (1)

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 091286

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 091286
Product	Strength	Form · route	Labeler	Product NDC
Gabapentin	Gabapentin 250 mg/5mL	SolutionOral	JVET PHARMACEUTICALS LLC	86211-112
Gabapentin	Gabapentin 250 mg/5mL	SolutionOral	Ajenat Pharmaceuticals LLC	82983-423
Gabapentin	Gabapentin 250 mg/5mL	SolutionOral	Kesin Pharma Corporation	81033-123
Gabapentin	Gabapentin 50 mg/mL	SolutionOral	Kesin Pharma Corporation	81033-123